These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 34546500)

  • 1. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
    Cazzaniga ME; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Di Mauro P; Cogliati V; Capici S; Clivio L; Torri V;
    Breast Cancer Res Treat; 2021 Dec; 190(3):415-424. PubMed ID: 34546500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.
    Cazzaniga ME; Pinotti G; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Fiorentini G; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Marchetti P; Melegari E; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Saracchini S; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Clivio L; Torri V;
    Breast; 2019 Dec; 48():7-16. PubMed ID: 31470257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients.
    Trevisan B; Pepe FF; Vallini I; Montagna E; Amoroso D; Berardi R; Butera A; Cagossi K; Cavanna L; Ciccarese M; Cinieri S; Cretella E; De Conciliis E; Febbraro A; Ferraù F; Ferzi A; Baldelli A; Fontana A; Gambaro AR; Garrone O; Gebbia V; Generali D; Gianni L; Giovanardi F; Grassadonia A; Leonardi V; Sarti S; Musolino A; Nicolini M; Putzu C; Riccardi F; Santini D; Sarobba MG; Schintu MG; Scognamiglio G; Spadaro P; Taverniti C; Toniolo D; Tralongo P; Turletti A; Valenza R; Valerio MR; Vici P; Clivio L; Torri V; Cazzaniga ME;
    Sci Rep; 2023 Jul; 13(1):12255. PubMed ID: 37507480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
    Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
    Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer.
    Chai Y; Liu J; Jiang M; He M; Wang Z; Ma F; Wang J; Yuan P; Luo Y; Xu B; Li Q
    Thorac Cancer; 2023 Aug; 14(23):2259-2268. PubMed ID: 37402471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
    Munzone E; Regan MM; Cinieri S; Montagna E; Orlando L; Shi R; Campadelli E; Gianni L; Palleschi M; Petrelli F; Bengala C; Generali D; Collovà E; Puglisi F; Cretella E; Zamagni C; Chini C; Ruepp B; Loi S; Colleoni M;
    JAMA Oncol; 2023 Sep; 9(9):1267-1272. PubMed ID: 37440239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
    Lee J; Kim HH; Ro SM; Yang JH
    PLoS One; 2017; 12(2):e0171605. PubMed ID: 28234911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
    Cazzaniga ME; Cortesi L; Ferzi A; Scaltriti L; Cicchiello F; Ciccarese M; Della Torre S; Villa F; Giordano M; Verusio C; Nicolini M; Gambaro AR; Zanlorenzi L; Biraghi E; Legramandi L; Rulli E;
    Breast Cancer Res Treat; 2016 Dec; 160(3):501-509. PubMed ID: 27752847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Experience of Metronomic Chemotherapy in Metastatic Breast Cancer: Results of a Retrospective Unicenter Study.
    Krajnak S; Krajnakova J; Anic K; Almstedt K; Heimes AS; Linz VC; Loewe A; Schmidt MW; Hasenburg A; Schmidt M; Battista MJ
    Breast Care (Basel); 2023 May; 18(2):97-105. PubMed ID: 37261128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study.
    Cerrito MG; De Giorgi M; Pelizzoni D; Bonomo SM; Digiacomo N; Scagliotti A; Bugarin C; Gaipa G; Grassilli E; Lavitrano M; Giovannoni R; Bidoli P; Cazzaniga ME
    Oncotarget; 2018 Jun; 9(44):27448-27459. PubMed ID: 29937997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
    Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
    BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
    Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
    Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
    Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
    Dranitsaris G; Gluck S; Faria C; Cox D; Rugo H
    Clin Ther; 2015 Jan; 37(1):134-44. PubMed ID: 25433768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Lahdenperä O; Kosonen S; Villman K; Nyandoto P; Nilsson G; Poikonen-Saksela P; Kataja V; Junnila J; Bono P; Lindman H
    JAMA Oncol; 2017 Jun; 3(6):793-800. PubMed ID: 28253390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
    Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center.
    Lu Q; Lee K; Xu F; Xia W; Zheng Q; Hong R; Jiang K; Zhai Q; Li Y; Shi Y; Yuan Z; Wang S
    Cancer Commun (Lond); 2020 May; 40(5):222-233. PubMed ID: 32390331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
    Wang Z; Liu J; Ma F; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Li Q; Xu B
    Breast Cancer Res Treat; 2021 Jul; 188(2):441-447. PubMed ID: 33895900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.
    Pepe FF; Cazzaniga ME; Baroni S; Riva F; Cicchiello F; Capici S; Cogliati V; Maggioni C; Cordani N; Cerrito MG; Malandrin S
    BMC Cancer; 2022 Sep; 22(1):956. PubMed ID: 36068484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project.
    Cazzaniga ME; Munzone E; Bocci G; Afonso N; Gomez P; Langkjer S; Petru E; Pivot X; Sánchez Rovira P; Wysocki P; Torri V
    Adv Ther; 2019 Feb; 36(2):381-406. PubMed ID: 30565179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.